Roche : FDA accepts REGEN-COV (casirivimab and imdevimab) for priority review for treatment and prophylaxis of COVID-19

Investor Update FDA accepts REGEN-COV (casirivimab and imdevimab) for priority review for treatment and prophylaxis of COVID-19

Dear Investor,

Please find attached a press release from our partner Regeneron:
https://investor.regeneron.com/news-releases/news-release-details/fda-accepts-regen-covr-casirivimab-and-imdevimab-priority-review

Do not hesitate to contact us for any further questions.

With best regards,

Roche Investor Relations
Dr. Karl Mahler Phone: [phone] e-mail: [e-mail]	Jon Kaspar Bayard Phone: [phone] e-mail: [e-mail]
Dr. Sabine Borngräber Phone: [phone] e-mail: [e-mail]	Dr. Bruno Eschli Phone: [phone] e-mail: [e-mail]
Dr. Birgit Masjost Phone: [phone] e-mail: [e-mail]	Dr. Gerard Tobin Phone: [phone] e-mail: [e-mail]
Investor Relations North America
Loren Kalm Phone: [phone] e-mail: [e-mail]